SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-297969"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-297969" > Cost-effectiveness ...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004134naa a2200433 4500
001oai:DiVA.org:uu-297969
003SwePub
008160629s2016 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:134296824
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-2979692 URI
0247 a https://doi.org/10.1038/tpj.2016.412 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1342968242 URI
040 a (SwePub)uud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Verhoef, T. I.u UCL, Dept Appl Hlth Res, London, England; Univ Utrecht, Div Pharmacoepidemiol & Clin Pharmacol, Dept Pharmaceut Sci, Utrecht, Netherlands4 aut
2451 0a Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden
264 c 2016-06-07
264 1b Springer Science and Business Media LLC,c 2016
338 a print2 rdacarrier
520 a We aimed to assess the cost-effectiveness of pharmacogenetic-guided dosing of warfarin in patients with atrial fibrillation (AF) in the United Kingdom and Sweden. Data from EU-PACT, a randomized controlled trial in newly diagnosed AF patients, were used to model the incremental costs per quality-adjusted life-year (QALY) gained by pharmacogenetic-guided warfarin dosing versus standard treatment over a lifetime horizon. Incremental lifetime costs were £26 and 382 Swedish kronor (SEK) and incremental QALYs were 0.0039 and 0.0015 in the United Kingdom and Sweden, respectively. The corresponding incremental cost-effectiveness ratios (ICERs) were £6 702 and 253 848 SEK per QALY gained. The ICER was below the willingness-to-pay threshold of £20 000 per QALY gained in 93% of the simulations in the United Kingdom and below 500 000 SEK in 67% of the simulations in Sweden. Our data suggest that pharmacogenetic-guided dosing of warfarin is a cost-effective strategy to improve outcomes of patients with AF treated with warfarin in the United Kingdom and in Sweden.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Hälsovetenskapx Hälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi0 (SwePub)303012 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Health Sciencesx Health Care Service and Management, Health Policy and Services and Health Economy0 (SwePub)303012 hsv//eng
7001 a Redekop, W. K.u Erasmus Univ, Inst Med Technol Assessment, Rotterdam, Netherlands4 aut
7001 a Langenskiöld, Sophieu Uppsala universitet,Hälsoekonomi,Karolinska Inst, Dept Learning Informat Management & Eth, Stockholm, Sweden4 aut0 (Swepub:uu)sopla565
7001 a Kamali, F.u Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England4 aut
7001 a Wadelius, Miau Uppsala universitet,Klinisk farmakogenomik och osteoporos,Science for Life Laboratory, SciLifeLab4 aut0 (Swepub:uu)miawadel
7001 a Burnside, G.u Univ Liverpool, Inst Translat Med, Block A,Waterhouse Bldg,1-5 Brownlow St, Liverpool L69 3GL, Merseyside, England4 aut
7001 a Maitland-van der Zee, A-H.u Univ Utrecht, Div Pharmacoepidemiol & Clin Pharmacol, Dept Pharmaceut Sci, Utrecht, Netherlands4 aut
7001 a Hughes, D. A.u Bangor Univ, Ctr Hlth Econ & Med Evaluat, Bangor, North Wales, Wales4 aut
7001 a Pirmohamed, M.u Univ Liverpool, Inst Translat Med, Block A,Waterhouse Bldg,1-5 Brownlow St, Liverpool L69 3GL, Merseyside, England4 aut
7102 a UCL, Dept Appl Hlth Res, London, England; Univ Utrecht, Div Pharmacoepidemiol & Clin Pharmacol, Dept Pharmaceut Sci, Utrecht, Netherlandsb Erasmus Univ, Inst Med Technol Assessment, Rotterdam, Netherlands4 org
7730 t The Pharmacogenomics Journald : Springer Science and Business Media LLCg 16:5, s. 478-484q 16:5<478-484x 1470-269Xx 1473-1150
8564 u https://www.nature.com/articles/tpj201641.pdf
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-297969
8564 8u https://doi.org/10.1038/tpj.2016.41
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:134296824

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy